POWER OF BLOGS

Insight Center: Blogs

CAFC Affirms PTAB's Decision To Invalidate Cialis and Adcirca Patents

Author: Reza Mollaaghababa

4/26/2018

Read the full post at Post-Grant Counsel

CAFC Affirms PTAB's Decision To Invalidate Cialis and Adcirca Patents

In a recent decision, the Court of Appeals for the Federal Circuit (CAFC) affirmed decisions in two inter-partes review (IPR) proceedings that patents owned by ICOS Corporation directed to tadalafil formulations (used in the erectile dysfunction drug, Cialis, and the pulmonary arterial hypertension drug, Adcirca) were invalid as obvious. (CAFC Decision Nos. 17-1071 and 1018, April 18, 2018.)

Data protection laws have changed, so we have revised our Privacy Policy.

CLOSE